Latest Ratios: P/E Ratio -0.9x · EV/EBITDA N/A · ROE -167.0%. (2006–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $32M | $42M | $38M | $135M | $257M | $124M | $95M | $32M | $41M | $44M | $42M |
| Enterprise Value | $-13987756 | $-3877588 | $-33442800 | $61M | $151M | $46M | $32M | $25M | $28M | $27M | $22M |
| P/E Ratio → | -0.94 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 359.07 | 471.40 | — | 1668.50 | 249.62 | 108.05 | — | — | — | — | — |
| P/B Ratio | 4.10 | 5.42 | 1.16 | 3.72 | 3.87 | 1.68 | 1.54 | 5.76 | 4.66 | 3.24 | 2.35 |
| P/FCF | — | — | — | — | 31.06 | — | — | — | — | — | — |
| P/OCF | — | — | — | — | 29.74 | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -43.08 | — | 747.95 | 146.39 | 40.29 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | 18.21 | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | — | 100.0% | 100.0% | 54.2% | — | — | — | — | — |
| Operating Margin | -40274.4% | -40274.4% | — | -64098.8% | -3311.1% | -2182.2% | — | — | — | — | — |
| Net Profit Margin | -37652.2% | -37652.2% | — | -60269.1% | -3205.5% | -2165.6% | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -167.0% | -167.0% | -110.6% | -94.9% | -47.2% | -36.7% | -66.3% | -302.9% | -210.4% | -167.9% | -121.7% |
| ROA | -52.7% | -52.7% | -48.3% | -49.9% | -33.9% | -33.8% | -56.9% | -164.9% | -142.4% | -130.2% | -99.0% |
| ROIC | — | — | — | — | — | — | — | — | — | — | — |
| ROCE | -64.4% | -64.4% | -59.5% | -58.8% | -38.5% | -36.9% | -65.9% | -291.3% | -211.8% | -169.9% | -134.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.22 | 0.22 | 0.05 | 0.06 | 0.04 | 0.00 | 0.01 | 0.25 | 0.03 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -5.91 | -2.18 | -2.05 | -1.60 | -1.05 | -1.03 | -1.39 | -1.52 | -1.27 | -1.14 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | -12.84 | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | -137.44 | -4955.99 | -5361.89 |
Net cash position: cash ($48M) exceeds total debt ($2M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.20 | 6.20 | 9.14 | 9.21 | 10.44 | 11.66 | 13.62 | 1.89 | 2.36 | 3.82 | 4.95 |
| Quick Ratio | 6.20 | 6.20 | 9.14 | 9.21 | 10.44 | 11.66 | 13.62 | 1.89 | 2.36 | 3.82 | 4.95 |
| Cash Ratio | 6.02 | 6.02 | 8.95 | 9.03 | 10.25 | 11.38 | 13.34 | 1.73 | 2.26 | 3.73 | 4.54 |
| Asset Turnover | — | 0.00 | — | 0.00 | 0.01 | 0.01 | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | 0.0% | 0.0% | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | 3.2% | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $31M | $30M | $27M | $24M | $21M | $12M | $5M | $4M | $2M | $2M |
Clinical and commercial execution
As reported in recent financial filings, ATNM trades at a price-to-sales multiple of 339.55, a figure that appears disconnected from fundamental performance and instead reflects market anticipation of the SIERRA trial outcomes rather than any established, recurring revenue stream or sustainable earnings power.
The extreme P/S ratio suggests that investors are pricing in a binary success scenario for Iomab-B rather than evaluating the company on current financial metrics. This valuation level warrants caution, as it implies a high growth trajectory that remains unproven given the company's pre-commercial status and the significant logistical hurdles inherent in its radiopharmaceutical business model.
Based on the provided quarterly data, the company's current ratio has fluctuated significantly, dropping from 10.59 in 2024Q1 to 5.89 in 2026Q1, which indicates a tightening liquidity position as the firm consumes its cash reserves to fund ongoing clinical and regulatory development activities.
While a current ratio above 5.0 appears healthy on the surface, it masks the reality of a company with limited cash-generating capacity and high fixed costs. Investors should monitor the rate of cash depletion relative to the BLA submission timeline, as the current liquidity profile may necessitate further dilutive financing to sustain operations through potential commercialization.
According to historical balance sheet data, the debt-to-equity ratio has trended upward from 0.04 in 2024Q2 to 0.66 in 2026Q1, signaling an increasing reliance on debt-like obligations as the company's total equity base has simultaneously contracted due to persistent, large-scale operating losses.
The rising leverage ratio is particularly concerning given the absence of positive EBITDA to service debt obligations. This trend suggests that the company is becoming increasingly vulnerable to credit market conditions, which may limit its financial flexibility as it attempts to build out the specialized infrastructure required for its radiopharmaceutical platform.
The most commonly misapplied metric for ATNM is the price-to-earnings ratio, which, at -0.89 TTM, fails to capture the company's true risk profile because it ignores the massive, non-recurring R&D investments and the unique logistical barriers to entry that define this specific radiopharmaceutical business model.
Analysts should instead prioritize tracking the 'Site Activation Rate' and 'Isotope Supply Security' as these operational metrics provide a more accurate assessment of the company's commercial viability than traditional accounting ratios. Relying on P/E or similar earnings-based multiples obscures the reality that the firm is currently an infrastructure-heavy development project rather than a mature, profit-generating enterprise.
Includes 30+ ratios · 20 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ATNM stock.
Actinium Pharmaceuticals, Inc.'s current P/E ratio is -0.9x. This places it at the 50th percentile of its historical range.
Actinium Pharmaceuticals, Inc.'s return on equity (ROE) is -167.0%. The historical average is -139.6%.
Based on historical data, Actinium Pharmaceuticals, Inc. is trading at a P/E of -0.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Actinium Pharmaceuticals, Inc. has 100.0% gross margin and -40274.4% operating margin.